We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors.
- Authors
Vera, K; Djafari, L; Faivre, S; Guillamo, J-S; Djazouli, K; Osorio, M; Parker, F; Cioloca, C; Abdulkarim, B; Armand, J-P; Raymond, E
- Abstract
Temozolomide has shown activity and limited toxicity in patients with primary brain tumors at doses of 150-200 mg/m(2)/day on days 1-5 every 4 weeks. In this study, a new alternative dose-dense regimen of temozolomide was explored in patients with recurrent brain tumors.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Vol 15, Issue 1, p161
- ISSN
0923-7534
- Publication type
Journal Article
- DOI
10.1093/annonc/mdh003